Temelimab as a Disease Modifying Therapy in Patients With Neuropsychiatric Symptoms in Post-COVID 19 or PASC Syndrome
Temelimab as a Disease Modifying Therapy in Patients With Neurological, Neuropsychological, and Psychiatric (=Neuropsychiatric) Symptoms in Post-COVID 19 or Postacute Sequelae of COVID-19 (PASC) Syndrome
Sponsor: GeNeuro SA
This PHASE2 trial investigates Post-COVID-19 Syndrome and is currently completed. GeNeuro SA leads this study, which shows 14 recorded versions since 2022 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Apr 2024 — Jun 2024 [monthly]
Active Not Recruiting PHASE2
▶ Show 9 earlier versions
-
Jan 2024 — Apr 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Oct 2023 — Jan 2024 [monthly]
Recruiting PHASE2
-
Aug 2023 — Oct 2023 [monthly]
Recruiting PHASE2
-
Jun 2023 — Aug 2023 [monthly]
Recruiting PHASE2
-
Apr 2023 — Jun 2023 [monthly]
Recruiting PHASE2
-
Feb 2023 — Apr 2023 [monthly]
Recruiting PHASE2
-
Dec 2022 — Feb 2023 [monthly]
Recruiting PHASE2
-
Nov 2022 — Dec 2022 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2022 — Nov 2022 [monthly]
Not Yet Recruiting PHASE2
First recorded
Aug 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GeNeuro SA
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Barcelona, Spain , Basel, Switzerland , Bern, Switzerland , Chur, Switzerland , Geneva, Switzerland , Madrid, Spain , Modena, Italy , Roma, Italy , Sion, Switzerland , Sterzing, Italy and 2 more locations